Messenger ribonucleic acid (mRNA) Synthesis Raw Materials Market Report 2026

The messenger ribonucleic acid (mrna) synthesis raw materials market size has grown steadily in recent years. It will grow from $3.03 billion in 2025 to $3.12 billion in 2026 at a compound annual growth rate (CAGR) of 3%. The growth in the historic period can be attributed to growing demand for vaccines, advances in molecular biology, increasing r&d investments in synthetic biology, rise of infectious disease outbreaks, development of efficient transcription enzymes.

The messenger ribonucleic acid (mrna) synthesis raw materials market size is expected to see steady growth in the next few years. It will grow to $3.65 billion in 2030 at a compound annual growth rate (CAGR) of 4%. The growth in the forecast period can be attributed to expansion of mrna-based therapeutics, adoption of automated mrna synthesis platforms, increase in personalized medicine initiatives, growth of biotechnology manufacturing hubs, innovations in nucleotide modifications. Major trends in the forecast period include synthetic mrna optimization, high-purity raw material development, scalable in-vitro transcription processes, supply chain standardization for mrna production, quality control & regulatory compliance.

The rising incidence of cancer and chronic disorders is expected to drive the growth of the mRNA synthesis raw materials market in the coming years. Cancer is a condition in which abnormal cells grow uncontrollably, invade nearby tissues, and may spread to other parts of the body through the blood and lymphatic systems. Chronic disorders are broadly defined as conditions that last for a year or longer, require ongoing medical care, limit daily activities, or involve a combination of these factors. mRNA synthesis raw materials are widely used in drug discovery, vaccine development, and the production of RNA-based therapeutics, as they offer advantages such as enhanced immunogenicity, higher production efficiency, and shorter manufacturing timelines for the treatment of cancer and chronic diseases. For instance, in January 2024, according to data published by the American Cancer Society, the United States was projected to record 2,001,140 new cancer cases and 611,720 cancer-related deaths in 2024, compared with 1,958,310 cases and 609,820 deaths in 2023. In addition, in September 2025, according to the British Heart Foundation, more than 7.6 million people in the UK, including over 4 million men and more than 3.6 million women, were living with cardiovascular disease, with projections indicating an increase of around 1 million affected individuals by 2030 and approximately 2 million by 2040 due to population aging and improved survival rates. Therefore, the growing burden of cancer and chronic disorders is driving demand for mRNA synthesis raw materials.

Major companies operating in the messenger ribonucleic acid (mRNA) synthesis raw materials market are emphasizing strategic collaborations to strengthen technological capabilities, expand high-quality raw material portfolios, and accelerate the production of next-generation mRNA therapeutics. Strategic collaborations involve formal partnerships among biotechnology companies, enzyme developers, and nucleic acid technology providers to co-develop advanced in vitro transcription enzymes, modified nucleotides, capping analogs, and other essential inputs that enhance mRNA yield, purity, stability, and safety. For example, in September 2024, TriLink Biotechnologies partnered with Alphazyme LLC to launch CleanScribe RNA Polymerase, a next-generation in vitro transcription enzyme that reduces double-stranded RNA formation by up to 85% during mRNA synthesis, supporting the development of safer and more effective mRNA-based therapeutics.

In February 2025, Maravai LifeSciences acquired the DNA and RNA business of Officinae Bio for an undisclosed amount. Through this acquisition, Maravai LifeSciences aims to enhance its nucleic acid production capabilities and strengthen its support for innovative mRNA and DNA therapeutic development.

Major companies operating in the messenger ribonucleic acid (mrna) synthesis raw materials market are Thermo Fisher Scientific Inc., Agilent Technologies Inc., Lonza Group Ltd., Bio-Rad Laboratories Inc., Qiagen N.V., Maravai LifeSciences, Takara Bio Inc., GenScript Biotech Corporation, Promega Corporation, Integrated DNA Technologies Inc., LGC Biosearch Technologies, Merck KGaA, GeneCopoeia Inc., Bio-Synthesis Inc., BOC Sciences Inc., Bio Basic Inc., OriGene Technologies Inc., BioCat GmbH, Creative Biogene, Jena Bioscience GmbH, ATDBio Ltd.

North America was the largest region in the mRNA synthesis raw materials market in 2025. The regions covered in the messenger ribonucleic acid (mrna) synthesis raw materials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the messenger ribonucleic acid (mrna) synthesis raw materials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the mRNA synthesis raw materials market by increasing the cost of importing essential nucleotides, enzymes, and plasmid DNA components, which are critical for vaccine and therapeutic production. The segments most affected include nucleotide and plasmid DNA suppliers, particularly in regions such as North America and Europe that rely heavily on imports from Asia. While tariffs have introduced supply chain challenges and cost pressures, they have also encouraged local manufacturing investments and diversification of sourcing strategies, which may strengthen domestic production capabilities over time.

The messenger ribonucleic acid (mrna) synthesis raw materials market research report is one of a series of new reports that provides messenger ribonucleic acid (mrna) synthesis raw materials market statistics, including messenger ribonucleic acid (mrna) synthesis raw materials industry global market size, regional shares, competitors with a messenger ribonucleic acid (mrna) synthesis raw materials market share, detailed messenger ribonucleic acid (mrna) synthesis raw materials market segments, market trends and opportunities, and any further data you may need to thrive in the messenger ribonucleic acid (mrna) synthesis raw materials industry. This messenger ribonucleic acid (mrna) synthesis raw materials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Messenger ribonucleic acid (mRNA) synthesis raw materials are ribonucleic components that support the accurate and efficient synthesis of mRNA molecules during in-vitro transcription processes, enabling the production of biologically functional synthetic RNAs. These materials are widely used in the manufacture of mRNA vaccines, which stimulate the body to generate an immune response against specific antigens, thereby enhancing overall immune capacity.

The main mRNA synthesis raw materials include capping agents, nucleotides, plasmid DNA, and others. Capping agents are amphiphilic molecules composed of a polar head group and a non-polar hydrocarbon tail, and they are used to introduce a modified cap structure onto an mRNA molecule during synthesis. This cap provides stability and protection to the mRNA, improving its translation efficiency and resistance to degradation. These raw materials are applied in areas such as therapeutic production, vaccine development, and other applications, and are used by biotechnology companies, pharmaceutical companies, research institutions, academic organizations, and others.

The mRNA synthesis raw materials market consists of sales of modified ribonucleoside triphosphates, polynucleotide tails, ribonucleoside diphosphate (NDPs), ribonucleoside monophosphate (NMPs), and ribonucleoside triphosphate (NTTs). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.